MicroPort® Receives China SDA Approval for Stent Size Extension for Firehawk® Stent System

Shanghai MicroPort Medical (Group) Co., Ltd. (“MicroPort®”) has recently been granted approvals for extending six new sizes to the approved product matrix for Firehawk® Rapamycin Target Eluting Coronary Stent System (“Firehawk®”) from China State Drug Administration (China SDA). The six additional sizes of Firehawk® have the same indications as those of the approved sizes, which consist of a balloon dilatation coronary stent, coating and a delivery system.

The revolutionary third-generation drug-eluting stent (“DES”) Firehawk® is the result of eight years of research and development of MicroPort® and it is the world’s first and only target eluting stent. As the world's lowest drug dosage stent, Firehawk® combines the merits of the bare metal stent and DES. It adopts unique in-groove abluminal coating design and target-eluting technique, which allow Firehawk® to achieve the same clinical efficacy with significantly low drug loading, benefiting vascular early healing.
MicroPort® Orthopedics Officially Launches the Instruments Kit for Domestically Made ADVANCE® That Applies Independent R&D to Meet the Needs of Chinese Patients

On July 5, MicroPort® Orthopedics China officially launched the independently developed ADVANCE® Total Knee Arthroplasty Instruments Kit (“ADVANCE®”) with an initial line-up of 33 components and 141 products. Compared to the imported instruments kit, MicroPort® Orthopedics China’s new kit targeting the domestic market apply a number of medical solutions that can better meet the needs of Chinese patients and surgeons more.

MicroPort® Orthopedics Medial Pivot Knee was launched in the US in 1998 with around 20 years’ clinical history. Up to date, nearly 600,000 Medial Pivot Knees have been implanted globally. Several long-term studies have proved the advantages of medial pivot knee in total knee arthroplasty (“TKA”). The Knee has published a study evaluating long-term clinical and radiographic outcomes of the Medial-Pivot Knee System. The results demonstrate excellent clinical outcomes for both satisfaction (95%) and survivorship (98.8%) at 17 years.
Firehawk® of MicroPort®
Makes Debut at Taipei Cheng Hsin Live

On July 21, Firehawk®, a star product independently MicroPort®, made its debut in the Taiwan market after being granted the registration approval by local authorities in January 2018. During the 2018 Taipei Endovascular Summit (Taipei Cheng Hsin Live) in conjunction with Taiwan Society of Cardiovascular Interventions (TSCI) Rota and Bifurcation Course, which was jointly held in Taipei by Cheng Hsin General Hospital, Hualien Tzu Chi Hospital and Nanjing First Hospital and also attended by MicroPort, several surgeries using Firehawk were live streamed to a wide audience.

In January, MicroPort® received the regulatory approval from Taiwan Food and Drug Administration ("TFDA") for its in-house developed Firehawk®. It is the first drug-eluting stent in MicroPort® and the whole Chinese mainland that successfully gained the regulatory approval in Taiwan. In May, Firebird2® Rapamycin-Eluting Coronary CoCr Stent System ("Firebird2™") also gain approval form TFDA.
MicroPort EP Attends 16th China Atrial Fibrillation Symposium (CAFS 2018)

From June 29 to July 1, the 16th China Atrial Fibrillation Symposium took place in Dalian, China. Shanghai MicroPort EP MedTech Co., Ltd. ("MicroPort EP") took part in all the sessions of the symposium with the presentation of the only domestically manufactured Columbus 3D EP Navigation System ("Columbus") and the auxiliary supplies, which drew great attention from the healthcare professionals in attendance.

Columbus™ 3D EP Navigation System, provides information about the electrical activity of the heart and catheter location in real time, is designed for the diagnosis of arrhythmias and acts as a guidance for catheter ablation.
MicroPort® Endovascular Attends the 12th Edition of China Southern Endovascular Congress (SEC 2018)

From July 13 to July 15, the 12th edition of China Southern Endovascular Congress (SEC 2018) and the 19th edition of Asia Endovascular Congress took place in Guangzhou. The scientific events were attended by specialists from more than 40 countries covering five continents, including the US, Britain, Germany, Japan, Korea, India and Malaysia, in addition to a great number of well-known Chinese vascular surgery specialists, which would promote the further development of the vascular surgery both in China and Asia. MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") held two academic salons focusing on the treatment strategies for aortic arch lesion and femoral popliteal artery lesion on the sidelines of the congress, deepening its communications with the experts in attendance.

During the sessions of SEC 2018, MicroPort Endovascular’s products won great recognition from a few more experts in the academic exchanges. Professor Zaiping Jing from Shanghai Changhai Hospital mentioned Castor®, the world’s first branch stent-graft system, which was jointly developed by MicroPort Endovascular and the hospital. Professor Chun-Che Shih from Taipei Veterans General Hospital demonstrated the endovascular repair of aortic dissection with Castor®. Professor Changwei Liu from Peking Union Medical College Hospital mentioned for several times the Reewarm® PTX, Minos™ Ultra Low-Profile Stent Graft System, and Castor® when discussing the innovation in domestically produced drug-coated balloon and aortic stent. Professor Tong Qiao from Nanjing Drum Tower Hospital reviewed the pre-market clinical trials of Castor®, adding that the follow-up study on the about 100 enrolled patients had showed positive results. Professor Qingsheng Lu from Shanghai Changhai Hospital said that Castor® is superior to in-situ fenestration technique with regard to endovascular repair of aortic dissection due to its easy and quick use, high branch patency rate, and less endoleak.
MicroPort Lifesciences Attends the 8th Edition of Diabetes and Gonadal Disorders Academic Conference

From July 20 to July 21, the 8th edition of Diabetes and Gonadal Disorders Academic Conference was launched in Beijing. Chinese Society of Endocrinology and Gonad Research Group and Diabetes Research Group jointly held the event. The conference attracted more than 500 experts in the field of diabetes and gonadal research. Experts held a deep discussion on the latest clinical researches, discipline constructions, and prevention and control of chronic diseases during the conference. Shanghai MicroPort Lifesciences Co., Ltd. ("MicroPort Lifesciences") participated in the conference and set up a booth. La Fenice® Insulin Pump and La Fenice® Hypophyseal Hormone Infusion Pump from MicroPort drew great attentions from the experts from home and abroad.

Professor Qiang Li, the standing committee of the Chinese Society of Endocrinology and the standing committee of the Chinese Endocrinologist Association, published a report entitled “diagnosis and treatment progress of IHH”. He said that three treatment methods of male IHH (Idiopathic Hypogonadotropic Hypogonadism, also known as "Kalman syndrome") among the mainstream programs, GnRH Infusion Pump therapy (Hypophyseal Hormone Infusion Pump therapy) is the most ideal treatment option for patients with fertility needs. Professor Li specifically praised the clinical therapeutic result of La Fenice® Hypophyseal Hormone Infusion Pump from MicroPort.

La Fenice® Hypophyseal Hormone Infusion Pump, jointly developed by Academician Guang Ning, local committee president of Chinese Endocrinologist Association from Ruijing Hospital Affiliated to Shanghai Jiao Tong University and MicroPort Lifesciences, is the first GnRH Infusion Pump that developed in China. Equipped with pulsatile infusion via micro pump technology, La Fenice® Hypophyseal Hormone Infusion Pump works as an artificial hypothalamus. This product allows patients to individualize the infusion setup, with micro-infusion, precise dose, and fast and powerful pulse infusion. In addition, La Fenice® Hypophyseal Hormone Infusion Pump is of high safety, and easy to operate and carry. By the end of 2017, hundreds of "MicroPort babies" had been born with the help of the La Fenice® Hypophyseal Hormone Infusion Pump, which brought much hope to a large number of IHH patients, especially those with childbearing desires.
MicroPort® EP Attends the China-Spain Electrophysiology Scientific Exchange Conference

Dr. Merino, who is a well-known Spanish Electrophysiologist, led a group of ten healthcare professionals from Spain to take part in the China-Spain Electrophysiology Scientific Exchange Conference at Shanghai Zhongshan Hospital Affiliated to Fudan University. MicroPort® EP was involved in all parts of the conference and presented during the surgery demonstration session the outstanding performance of the only domestically-manufactured 3D EP navigation system featuring real time magnetic device tracking - Columbus® 3D EP Navigation System (“Columbus”), which attracted the attention of the Spanish healthcare professionals.

The Columbus® is China’s first independently developed 3D EP navigation system featuring real time magnetic device tracking with cardiac motion compensation, and the only domestically made system of its likes with the CE certificate thus far. Its properties include accurate geometric reconstruction of intracardiac structure, automatic 3D image segmentation of cardiac chambers with one mouse click, accurate preoperative CT image registration and integration, vivid 3D simulation of the catheter deflectable segment and integrated electrophysiological multidetector, which facilitates the clinicians’ observation and operation and effectively shorten the users’ learning curve. Combined with the matching products including FireMagic™ Cool 3D Irrigated Ablation Catheter with real-time cardiac motion compensation, Columbus® can provide complete 3D Navigation equipment and catheter solutions in the field of arrhythmia radiofrequency ablation. It has won unanimous recognition among the domestic and international clinicians for its outstanding clinical performance since its release to market.
**SuperPath®** Helps

**a Second Centenarian Walk Again**

A 100-year-old patient recently underwent a successful minimally invasive hip replacement surgery with good recovery at the Orthopedics Center of Huaihua City No. 1 People’s Hospital in Hunan province, China, becoming the second centenarian in China to benefit from SuperPath® Superior Percutaneously Assisted Total Hip (“SuperPath™”) after a 103-year-old patient from Zhenjiang, Jiangsu province in December 2017.

SuperPath® causes incision as little as a 3-inch and ensures the maximum protection of soft tissue, leading to fewer post-operative restrictions, faster return to function, and improved satisfaction for patients. Patients can walk as early as four hours after surgery.
For more information, please contact:

**Martin Sun**  
Chief Financial Officer  
MicroPort Scientific Corporation  
Tel: (86)(21) 38954600  
Email: ir@microport.com

**Leanne Li**  
Board Secretary & VP of Corporate General Affairs  
MicroPort Scientific Corporation  
Tel: (86)(21) 38954600  
Email: ir@microport.com